USANA Health Sciences (NYSE: USNA) reported Q3 EPS of $2.40, $0.27 better than the analyst estimate of $2.13. Revenue for the quarter came in at $254.2 million versus the consensus estimate of $263.37 million.

GUIDANCE:

USANA Health Sciences sees FY2016 EPS of $7.90-$8.10, versus prior guidance of $7.90-$8.20 and the consensus of $8.10. USANA Health Sciences sees FY2016 revenue of $1.00-1.01 billion, versus the consensus of $1.03 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.